Jpmorgan Chase & CO Gossamer Bio, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 694 shares of GOSS stock, worth $617. This represents 0.0% of its overall portfolio holdings.

Number of Shares

694

Previous 201,898 99.66%

Holding current value

$617

Previous $238,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.51 - $1.27 $102,614 - $255,529	-201,204 Reduced 99.66%	694 $0
Q1 2024 May 10, 2024	BUY	$0.8 - $1.51 $161,518 - $304,865	201,898 New	201,898 $238,000
Q3 2023 Nov 14, 2023	BUY	$0.78 - $1.82 $30,909 - $72,121	39,627 Added 1001.69%	43,583 $36,000
Q2 2023 Aug 11, 2023	SELL	$0.98 - $1.53 $113,363 - $176,985	-115,677 Reduced 96.69%	3,956 $4,000
Q1 2023 May 18, 2023	BUY	$0.96 - $2.92 $82,503 - $250,947	85,941 Added 255.08%	119,633 $150,000
Q1 2023 May 11, 2023	SELL	$0.96 - $2.92 $848,521 - $2.58 Million	-883,877 Reduced 96.33%	33,692 $42,000
Q4 2022 Feb 13, 2023	BUY	$1.74 - $12.87 $1.47 Million - $10.9 Million	844,868 Added 1162.11%	917,569 $1.99 Million
Q3 2022 Nov 14, 2022	BUY	$7.21 - $14.88 $98,755 - $203,811	13,697 Added 23.21%	72,701 $871,000
Q2 2022 Aug 11, 2022	SELL	$5.97 - $9.97 $306,314 - $511,550	-51,309 Reduced 46.51%	59,004 $495,000
Q1 2022 May 11, 2022	BUY	$8.44 - $12.49 $540,860 - $800,396	64,083 Added 138.62%	110,313 $957,000
Q4 2021 Feb 10, 2022	BUY	$10.12 - $14.07 $37,292 - $51,847	3,685 Added 8.66%	46,230 $523,000
Q3 2021 Nov 12, 2021	BUY	$7.25 - $13.23 $308,451 - $562,870	42,545 New	42,545 $535,000

Others Institutions Holding GOSS

# of Institutions

104

Shares Held

175M

Call Options Held

453K

Put Options Held

543K

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $83.6M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Gossamer Bio, Inc. Transaction History